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I. Introduction
It is a great privilege to have been selected by
the Japanese Dermatological Association to
present the prestigious Dohi Memorial Lecture
for 1996. The individuals who have presented
the Dohi Lecture have been or are the giants of
our specialty. I am honored by the Japanese
Dermatological Association's decision to in-
clude me among these leaders.
I am especially pleased to deliver the Dohi
lecture at this time because this is the year my
friend Professor Akira Ohkawara is President
of the Japanese Dermatological Association.
My career in psoriasis research began based on
the landmark paper published in 1966 by
Professors Ohkawara and Halprin (1). This
paper and subsequent papers derived from it
guided my research until the early 1980s.
n. The Epidermis and Psoriasis
In the late 1960s the epidermis of psoriasis
was known to be characterized by increased
proliferation (2). Researchers and clinicians
alike were inspired by the striking epidermal
downgrowth but were unimpressed by the
comparatively sparse inflammatory infiltrate.
Since the epidermal changes were so impres-
sive, most workers considered the inflamma-
tory cells as a secondary reaction to the epi-
dermal pathology. Indeed, the epidermis and
its accelerated growth were considered by most
people to be at the heart of the disease. The
assumption was that the psoriasis patient pos-
sessed genetic defects which when expressed
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in the epidermis would lead to excessive epi-
dermal cell proliferation. Thus the root cause
of the disease was believed to reside mainly or
entirely within the epidermis. However, the
fundamental nature of this epidermal defect
was a complete mystery.
A first clue came in the paper by Professor
Ohkawara who working with Kenneth Halprin
demonstrated that glycogen was markedly
elevated in the differentiating layers oflesional
epidermis (1). At about this time it was also
known from the work of Earl Sutherland that
glycogen could be broken down by cyclic AMP
(3). Then William Bullough and colleagues
demonstrated that epinephrine had the ability
to inhibit epidermal cell division. Epinephrine
had also been shown to raise cyclic AMP in
cells (3).
Based on these observations we developed
the hypothesis which stated that within psori-
atic epidermis the ability to maintain normal
levels of cyclic AMP might be impaired. The
idea was that a low or an unstable level ofcyclic
AMP could account for both glycogen accumu-
lation in the outer layers and increased pro-
liferation in the inner layers of lesional epi-
dermis (4). However, several years of research
by our group as well as that of Halprin failed to
provide data which could definitively implicate
the cyclic AMP system as a key mediator of
psoriatic epidermal pathology.
Although a role for cyclic AMP had not been
proven, we embarked on a search for locally
formed substances which could regulate cyclic
AMP synthesis. This research directed our
attention to the eicosanoids. Certain eicosa-
noids (including prostaglandin E2) were known
to regulate cyclic AMP and to also cause
vasodilation (a feature of psoriatic lesions). In
1975, we published our first paper on eicosa-
noids which demonstrated markedly increased
levels of arachidonic acid, 12-hydroxyeicosa-
tetraenoic acid and prostaglandin E2 (5).
852 Voorhees
Fig. 1. Overview of the activated skin immune
system in psoriasis. See text for explanation.
early 80s because it had been reported to
inhibit the formation of leukotriene B4 (8). In
the early 80s we still believed that leukotriene
B4 was important because the many negative
leukotriene B4 inhibitor clinical trials had not
yet been performed. Therefore, cyclosporine's
ability to inhibit leukotriene B4 was the
rationale for our first trial of cyclosporine in
psoriasis. The results of this trial, the first
double-blind trial of cyclosporine in psoriasis
in the world, confirmed the open study of
Mueller and Herrmann. Our double-blind
study was published in late 1986 (8). However,
also in late 1986, Griffiths and Fry, working
independently in England, published an open
study which taken together with our double-
blind study provided definitive proof of cyclo-
sporine's efficacy in psoriasis (8, 9).
Although we had undertaken the cyclo-
sporine trial because it was said to inhibit
leukotriene B4, literature was rapidly appearing
which indicated that the primary action of
cyclosporine was to inhibit lymphokine release
and proliferation ofT cells. At around this time
Dr. Kevin Cooper, who had been trained by
Steve Katz, was appointed Assistant Professor at
our Department of Dermatology. This was the
beginning of a 10-year collaboration between
Cooper and myself during which time we, as
well as many other researchers, established
that in psoriasis the immune system plays an
important role. Today it is widely accepted that
although the cause of the disease is unknown,
the T cell is a critical mediator of the clinical
expression of the disease. For this reason, in
Although our work on eicosanoids began in an
attempt to better understand the cyclic AMP
system in epidermis, ongoing research by other
workers showed that eicosanoids were major
mediators of inflammation in a variety of
disease settings.
A turning point came in 1983 when Knud
Kragballe in Denmark discovered that benoxa-
profen could markedly improve psoriasis.
Benoxaprofen was a known inhibitor of 5-
lipoxygenase, the enzyme responsible for the
formation of leukotriene B4 • As a result of his
discovery, Kragballe came from Denmark to
Ann Arbor and together we formulated the
hypothesis that leukotriene B4 may be critical to
the inflammatory and proliferative processes in
psoriasis (6). This hypothesis was well received
since not only did the 5-lipoxygenase inhibitor
(benoxaprofen) improve psoriasis, but we had
also previously detected striking increases in
the substrate (arachidonic acid) of 5-lipoxy-
genase within lesions of psoriasis (5).
Our initial publication in 1975 (5) and the
5-lipoxygenase hypothesis (6) prompted phar-
maceutical scientists to design many 5-lipoxy-
genase inhibitors for use in psoriasis. Since the
mid-80s we and others have performed clinical
trials on over one dozen such inhibitors with-
out a single convincing result. It appears that
the drugs do not enter the skin, or benoxa-
profen has other activities which caused
psoriasis to clear, or the leukotriene pathway is
too far downstream for drug blockade to make
a clinical difference.
ill. Immunology and Psoriasis
Although inflammation (especially polymor-
phonuclear leukocytes) had been discussed in
the context of psoriasis, it was not until the
1979 report of Mueller and Herrmann, whose
serendipitous discovery that cyclosporine could
clear psoriasis, that immunology began to be
considered in psoriasis (7). At that time cyclo-
sporine was primarily used to prevent trans-
plant rejection and was little used for other
immunological diseases. For this reason and its
unfamiliarity to us we did not seriously consider
an immunologic basis for psoriasis at that time.
Rather, we were drawn to cyclosporine in the
en
w
z
52
o
l-
t
~ATINOC~~-"'"
PERPETUATE
IINFLAMMATIONI~--
Psoriasis-An Immunological Disease 853
the remainder of this lecture I will provide an
overview of our current understanding of the
immunological basis of psoriasis. Although
cyclic AMP and leukotrienes may playa role in
lesional molecular pathology, the immunologi-
cal aspects of psoriasis are so compelling that
we no longer investigate these latter two areas.
IV. The Skin Immune System in Psoriasis
Psoriatic epidermis is characterized by not
only increased cell proliferation but also
keratinocyte activation. Activated keratinocytes:
release cytokines of several types which cause
inflammation and perpetuation of a classical
cell-mediated immune response. Within lesions
the immune response is characterized by an
interaction between antigen-presenting cells
(APC) and T cells (10). As shown in Figure 1
this interaction occurs as an antigen is being
presented to lesional T cells by lesional APCs.
The APCs have on their surface either major
histocompatibility class (MHC) I or class II
molecules. The antigen to be presented to the
T cell is lodged in either the MHC class I or II
binding pocket on the APC.
In psoriasis the identity of this antigen has
yet to be found. However, whatever the identity
of the psoriasis antigen(s), it is likely to be a
protein. Such proteins are chopped into small
peptides by the APC and it is these peptides
that then fit into MHC class I or II for
presentation to T cells. Although the psoriasis
antigen(s) has yet to be identified, it is likely
that one such peptide will be derived from a
streptococcal antigen. It is commonly known
that a sizable fraction of patients with acute
guttate psoriasis have as a precipitating factor,
an antecedent streptococcal infection (11).
However many patients, especially those with
plaque psoriasis, have no detectable strepto-
coccal infection. For this reason, it may be that
several different foreign or auto-antigens may
trigger the APC-T cell interaction in patients
with suitable genetic susceptibility.
V. Antigen Presenting Cells in Psoriasis
In normal human skin APCs are represented
by MHC II (HLA-DR+) positive Langerhans
cells. We therefore sought to identify those
APCs contained within psorrauc lesions. We
demonstrated that CDla+DR+ Langerhans cells
are present in similar numbers in lesional and
non-Iesional skin and therefore were unlikely
to be the pathogenic APCs in lesions. However,
when CDla-DR+ cells were removed from
lesional cell suspensions, the APG activity was
markedly reduced. Thus the APC activity
driving T cells within lesions is composed of
non-Langerhans cell CDla-DR+ macrophage-
like cells (12).
However, more recently it has been shown
that a second type of APC is present within
lesional dermis. This APC has been termed the
dermal dendrocyte, is located in the high
papillary dermis around blood vessels, and is
factor-XIIIA positive. These APCs are also
activated and, thus, it appears that in psoriatic
lesions at least two types of APCs are respon-
sible for the heightened APC activity found in
lesions. This leads to the hypothesis that
lesional APCs promote lesional T cell activation
by presenting the T cell with either a foreign or
a self antigen.
A corollary of this hypothesis is that psoriasis
genes encode susceptibility to skin autoim-
munity. Activated T cells in this scenario would
release lymphokines which directly or in-
directly induce keratinocyte proliferation and
altered epidermal differentiation. In this con-
text a major pathophysiological pathway in
psoriasis 'is autoimmune wounding of the epi-
dermis. Thus, psoriasis may be considered as
another example of a T cell mediated auto-
immune disease. In fact the only missing link
appears to be the identity of the antigens which
in the proper genetic context can trigger T cell
activation. Thus, the thinking in psoriasis
research has undergone a major shift away
from one of epidermal causation to one of an
epidermal response (i.e. chronic proliferation
and disordered differentiation) to immunologic
injury.
VI. T Cells in Psoriasis
In psoriatic lesions both CD4+ and CD8+ T
cells have been described (reviewed in ref 10).
Furthermore, although both types of T cells
have been found in epidermis and dermis of
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Fig. 2. Regulation of cytokine gene transcription in activated T cells. An X marks the site of inhibition that
characterizes anti-psoriasis drugs. RAPA-rapamycin; GR, RAR and VDR-glucocorticoid, retinoid, and
vitamin D3 receptors, respectively; CSA-cyclosporine. A detailed description of this diagram can be found
in the text.
lesions, a majority of T cells in the dermis are
CD4+ and in the epidermis are CD8+ (13).
Psoriasis has a strong association with both
HLA-Cw6 and DR7. The interest in HLA
associations stems from the fact that inherited
differences in HlA (MHC) proteins could
account for why one person with a certain HlA
phenotype manifests psoriasis and another
person who inherited a different protein
phenotype does not. In other words one type of
inherited HLA phenotype would present an
antigen to a T cell while another phenotype
could not do so. It is interesting to note that
CD4+ T cells interact with APCs carrying MHC
class II (eg. HLA-DR7+) and CD8+ T cells
interact with APCs which express MHC class I
(eg. HLA-Cw6+). Thus the presence of both
CD4+ and CD8+ T cells in lesions is in accord
with the strong association of psoriasis with
both class I and II MHC molecules.
In lesions the presentation of an antigenic
peptide by an MHC molecule on the surface of
an APC to the T cell receptor on the surface of
a T cell can be considered by analogy to a
hormone and its receptor. In this comparison
the antigenic peptide is the hormone and the T
cell receptor on the T cell is the hormone
receptor. Like a hormone binding to its cognate
receptor, the antigen upon binding to its T cell
receptor stimulates a signal transduction cas-
cade within the T cell. As shown in Figure 2,
this signalling utilizes protein kinase C, cal-
cineurin phosphatase, costimulatory signals
CD28 and CTLA-4, activating protein I (AP-I),
and nuclear factor of activated T cells (NFAT).
Thus, recognition of an antigen by its receptor
on the surface of a T cell causes a molecular
cascade to occur which terminates on enhancer
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Table 1. Ternary complex therapy of psoriasis
complex is believed to be sufficient to cause
clinical disease. Autoimmune diseases other
than psoriasis believed to be caused by different
ternary complexes are multiple sclerosis, insu-
lin-dependent diabetes, inflammatory bowel
disease, and rheumatoid arthritis (19).
Since the entire intact ternary complex is
necessary for immune mediation, it follows that
impairment of any part of the complex should
be sufficient to improve disease. The table lists
many drugs which have been used or are
experimentally being used to treat psoriasis.
Although many agents listed in the Table 1
may have multiple pharmacologic effects, they
all have one mechanism in common, immuno-
suppression. Methotrexate promotes the ac-
cumulation of extracellular adenosine which
via A2 .receptors causes immunosuppression
(20). Sulfasalazine appears to act via a similar
mechanism ofadenosine accumulation (20, 21).
UV irradiation appears to cause immunosup-
pression by inducing the formation of IL-I0
(22, 23) which is believed to be a natural
suppressant of the cutaneous inflammatory
response (24). Thus a well controlled trial of
IL-I0 in psoriasis would appear to be in order.
Cyclosporine, FK506, ascomycin and rapa-
mycin all impair the signal transduction
mechanism within T cells and thereby block T
cell growth and cytokine (eg. IFNI') release (see
Figure 2 which has the site of action of these
drugs indicated). Although steroids, retinoids
and vitamin D have multiple actions, they too
block T cell signalling at the level ofNFKB and
NFAT/ AP-l thereby impairing the transcrip-
elements within the promoters of cytokine
genes in T cells. This results in the production
of IL-2 for T cell proliferation and the produc-
tion of interferon I' (IFNI') and IL-4 for various
kinds of T cell mediated responses.
Abundant evidence exists to substantiate the
presence of activated (and therefore potentially
disease causing) T cells within lesions. The
ultimate manifestation of T cell activation is T
cell proliferation. Using a marker for cell
proliferation we reported that 37% of all pro-
liferating cells within the dermis of lesions
were CD45 RO+ memory T cells (14). In
addition other well accepted markers of T cell
activation are present on lesional T cells such
as HLA-DR and IL-2 receptor positivity.
Activated T cells in general produce one of
two types of lymphokines (cytokines derived
from T cells). T-l lymphokines are IL-2 and
IFNI' which mediate cellular immunity and T-2
lymphokines are IL-4, 5 and 10 which mediate
humoral immunity. T cells within lesions have
been shown to produce the T-1 lymphokines,
IL-2 and IFNI' (15-17). The injection ofIL-2 or
IFNI' into psoriasis patients has resulted in
disease flares in significant numbers ofpatients
(reviewed in ref 10). In addition, lymphokine-
containing supernatants, prepared from T cells
cloned from psoriatic lesions, caused the pro-
liferation of uninvolved psoriatic keratinocytes
when the supernatants were added to the
keratinocytes in vitro. If neutralizing antibodies
to IFNI' were added to the supernatants prior to
addition to keratinocyte cultures, keratinocyte
growth was inhibited (18). These data indicate
that IFNI' released from T-l type T cells within
lesions is likely to be a critical factor in disease
pathogenesis.
VII. Immunotherapy of Psoriasis
So it is, that based on the above discussion,
the treatment of psoriasis has been sharply
focused on the lesional immune system and
away from the epidermis as an organ respond-
ing to immune injury. The immunological unit,
the APC-antigen-T cell, which is found in the
psoriatic lesion is called by immunologists the
ternary complex. This complex is a hallmark of
a T cell mediated disease. Activation of this
e MTX (Adenosine-Aj)
e 2-Chlorodeoxyadenosine
e Sulfasalazine
eUVB
ePUVA
e T-Cell Death (IL-2-Toxins)
eCSA
eFK506
eAscomycin
eRapamycin
eSteroid
eRetinoid
eVitamin n,
eAnti CD3
eAnti CD4
eCTLA-4Ig
e Peptide Vaccine
e IL-IO
e Anti-IL-12
eAnti-IFNy
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tion of lymphokine genes in T cells (25, 26).
Anti-CD3 and anti-Clj, also block T cell sig-
nalling but in contradistinction to the above
agents, the antibodies bind to their cognate T
cell surface proteins and impair T cell activa-
tion from its initiation at the T cell surface
(reviewed in 10). In addition to activation of the
T cell receptor by antigen, a productive T cell
activation also requires a second signal called
the B-7/CD28 pathway. A molecule known as
CTLA-4Ig binds to B-7 and prevents it from
interacting with CD28 to provide the 2nd signal
(27). This causes immunosuppression by in-
ducing T cell antigen desensitization, anergy or
apoptosis. CTLA-4Ig is currently being tested
for possible utility in psoriasis.
VIll. Perspectives
Thus in the 30 years since Professor
Ohkawara and I have been investigating
psoriasis, a major paradigm shift has occurred,
largely due to the advent of cydosporine. In
the early years psoriasis was thought to be an
epidermal disease. Now we know that psoriasis
is driven by the activated cellular immune
mechanism discussed above. Now and in the
future, new therapies will be studied for their
ability to impair the local lesional hyperactive
immune response. Although the immune re-
sponse is appreciated to be the critical driver of
disease expression, the cause of psoriasis re-
mains unknown. In an attempt to address the
cause of this disease we have undertaken a
molecular genetic analysis of psoriasis. It is our
hope that this approach will lead to identifica-
tion of those genes which cause this disease.
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